双靶向溶瘤病毒在晚期实体瘤中显示出临床疗效。
A Dual-Armed Oncolytic Virus Shows Clinical Efficacy in Advanced Solid Cancers.
机构信息
Division of DNA and RNA Medicine, CCUN, Pamplona, Spain.
Instituto de Investigación Sanitaria de Navarra (IdISNA) and CCUN, Pamplona, Spain.
出版信息
Clin Cancer Res. 2024 Sep 3;30(17):3649-3651. doi: 10.1158/1078-0432.CCR-24-1126.
An oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 was tested in patients with advanced solid tumors. Antitumor effects were observed in both treated and non-treated lesions, leading to long-term survival in some patients. This clinical trial shows the potential of oncolytic virotherapy for patients refractory to standard therapies. See related article by Pakola et al., p. 3715.
一种携带肿瘤坏死因子-α和白细胞介素-2 的溶瘤腺病毒在晚期实体瘤患者中进行了测试。在治疗和未治疗的病变中都观察到了抗肿瘤作用，导致一些患者长期生存。这项临床试验表明，溶瘤病毒疗法对标准治疗耐药的患者具有潜在疗效。见 Pakola 等人的相关文章，第 3715 页。
Zotero 插件